GSK3B and hepatocellular carcinoma: Another therapeutic strategy could be based on the reduction of GSK3β in tumor-associated macrophages (TAMs) to prevent HCC development through the inhibition of M2 phenotype and increase the sensitivity of anti-programmed death 1 (PD1) immunotherapy by the decrease of Programmed Death-Ligand 1 (PD-L1) ubiquitination [151].